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 Vitamin K2 blocks IFN-α-2b-induced reduction in size and volume of the altered 
hepatic foci in rats  
 Vitamin K2 inhibits IFN-α-2b-induced apoptosis in rat preneoplastic livers  
 Vitamin K2 inhibition of IFN-α-2b-induced apoptosis is mediated by increased levels of 
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Objective: Vitamin K2 is present in dairy products, and it has been recommended its 
supplemteation as a micronutrient in humans. Vitamin K2 has special interest as it holds 
anticancerous properties. On the other hand, IFN-α-2b administered during development of 
hepatic preneoplasia decreased both number and volume percentage of altered hepatic foci 
(AHF) by increasing apoptosis in the foci. The aim of this study was to evaluate the effects of 
IFN-α-2b treatment supplemented with vitamin K2 in an early stage of liver cancer development 
in rats.  
Methods: Adult male Wistar rats were subjected to a two-phase model of hepatocarcinogenesis 
(initiated-promoted, IP group). Animals were divided into 4 groups: untreated (IP), IP treated 
with IFN-α-2b (6,5x10
5 
U/Kg), IP treated with vitamin K2 (10 mg/Kg), and IP treated with both 
compounds.  
Results: We found that vitamin K2 blocks IFN-α-2b-induced reduction in size and volume of 
the altered hepatic foci. Also, vitamin K2 inhibits IFN-α-2b-induced apoptosis, and finally, 
vitamin K2 inhibition of IFN-α-2b-induced apoptosis is mediated by increased levels of total 
hepatic Bcl-2 in rat preneoplastic livers. 
Conclusion: These findings highlight that supportive vitamin supplements/therapies are not 
always safe, as they could put at risk the life of patients treated with IFN-α-2b. 
 




HCC, hepatocellular carcinoma; AHF, altered hepatic foci; ROS, reactive oxygen species; MK, 
menaquinone; DEN, diethylnitrosamine; 2-AAF, 2-acetylaminofluorene; rGST-P, anti-pi class 
of rat glutathione S-transferase antibody; PCNA, proliferating cell nuclear antigen; IP, initiated-
















Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with an 
estimated incidence of more than one million new cases per year 
[1]
. Many cancer patients 
combine some forms of complementary and alternative medicine therapies with their 
conventional therapies. The most common choice of these treatments is the nutritional 
administration of certain essential compounds such as vitamins 
[2][3]
. In these connection, 
vitamin K is a fat-soluble essential vitamin; its only known physiological role is as a cofactor 
for γ-glutamyl-carboxylase, which acts on several blood-clotting proteins 
[4]
. Vitamin K is 




There are three types of vitamin K: naturally occurring vitamin K1 (phylloquinone) and 
vitamin K2 (menaquinone, MK) and chemically synthesized vitamin K3 (menadione). Vitamin 
K1 and vitamin K2 are non-toxic even at high doses. Vitamin K3 is toxic causing hemolytic 
anemia, liver toxicity and allergic reactions 
[6]
. 
Vitamin K2 is also known as MK-n (n =1 to 14), where n stands for the number of 
repeating isoprenyl units in its side chain. The most common form of vitamin K2 in animals is 
MK-4, which is produced by intestinal bacteria or is metabolically converted from other 
vitamins K 
[7]




Vitamin K2 is present in dairy products, such as meat and eggs 
[9]
. Epidemiological 
studies have indicated that populations taking these foods rich in micronutrients have lower 
incidence of cancer or cancer mortality 
[10]
. In this connection, it was suggested that 
micronutrients may have some anticancer properties 
[11]
. Therefore, there is a significant interest 
in determining whether vitamin K2 offers protection against HCC 
[10][11]
.  
There has been continuing interest for the use of vitamin K2 in the chemoprevention of 
HCC in Asian countries due to its long-term safety 
[12]
. It has been shown that vitamin K 














HCC cells in vitro and in vivo with little, if any, toxicity in adult HCC patients 
[13]
. However, the 
precise mechanism of its antitumoral action has not been clarified, yet. A few studies have 
demonstrated reduction of HCC recurrence upon vitamin K2 supplementation; however, to 
confirm the beneficial effect or lack of it upon vitamin K2 administration, larger, higer quality  
trials are still required 
[14][15]
.   
Recent studies have shown that vitamin K2 can be combined with antitumor drugs to 
enhance their antiproliferative effects. It has been reported that the combined use of perindopril, 
an angiotensin-converting enzyme inhibitor drug, with vitamin K2 attenuates preneoplastic 
hepatic lesions in rats 
[16]
. Even more, a synergistic action that suppresses cell migration of 
human hepatoma cells has also been demonstrated with sorafenib, the only drug approved by 
the FDA for the specific treatment of liver cancer 
[17]
.  
IFN is known to be a multifunctional cytokine exhibiting various biological 
functionsand it has been used for antiviral treatment in patients with chronic hepatitis C 
[18]
. 
IFN-α has been shown to induce apoptosis in tumor cells in vivo using a similar dose to that 
used clinically 
[19]
. It has been stated that IFN-α applied in the early stages of tumor 
development could have an important clinical effect 
[20]
. In this regard, we have demonstrated 
that IFN-α-2b administered during the development of hepatic preneoplasia significantly 
decreased both number and volume percentage of altered hepatic foci (AHF) by an increased 
programmed cell death in the foci. The apoptotic effect of IFN-α-2b on preneoplastic livers was 
mediated by an increase in reactive oxygen species (ROS) and depends, to a large extent, on the 
deregulation of the Bcl-2 family, with a substantial increase in Bax levels in mitochondria and 
overexpression of p53 
[21]
. 
In the present study we evaluated the effects of adding vitamin K2 to the traditional 
IFN-α-2b treatment in an early stage of liver cancer development in rats. The effects of this 














Materials and Methods 
Chemicals 
Diethylnitrosamine (DEN), 2-acetylaminofluorene (2-AAF), and vitamin K2 (MK-4) were 
obtained from Sigma Chemical Co. (St. Louis, MO, USA). IFN-α-2b was obtained from 
BioSidus Laboratory (Buenos Aires, Argentina) and anti-P class of rat glutathione S-transferase 
(rGST-P) antibody from Stressgen Bioreagents (Ann Arbor, MI, USA). Antibodies against Bax, 
Bcl-2, Bcl-xL, cytochrome c, proliferating cell nuclear antigen (PCNA), cyclin D1, p27, and p53 
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Pierce-enhanced 
chemiluminescence (ECL) Western Blotting Substrate was from Thermo Fisher Scientific 
(Rockford, IL, USA). All other chemicals were of the highest grade commercially available. 
 
Animals and Treatment 
Adult male Wistar rats (from ICIVET Litoral, UNL-CONICET) (250–280 g) were maintained 
in suspended stainless steel wire-bottom cages to prevent coprophagy (2 per cage) in a room at 
constant temperature with a 12 h light–dark cycle, with food and water supplied ad libitum. 
Experimental protocols were performed according to the NIH “Guide for the Care and Use of 
Laboratory Animals” (Publication no. 25-28, revised 1996), and approved by the local animal 
care and use committee.  
All animals were subjected to a 2-phase model of rat hepatocarcinogenesis (initiation-
promotion, IP). An overview of the experimental setup is provided in Fig. 1A. The initiation 
stage was performed by the administration of 2 intraperitoneal necrogenic doses of DEN (150 
mg/kg body weight) 2 weeks apart. Administration of 2-AAF was performed 1 week after the 
last injection of DEN. The 2-AAF was dissolved in dimethyl sulfoxide and then suspended in 
corn oil to a final concentration of 8 mg/mL. The rats received 20 mg/kg body weight of 2-
AAF/corn oil suspension by gavage for 3 consecutive days per week for 3 weeks. After the IP 
treatment, animals were divided into 4 groups of 5 rats each: IP, IP-IFN (from now on group 
IFN), IP-VK2 (from now on group VK2) and IP-IFN+VK2 (from now on group IFN+VK2). 
Group IFN received IFN-α-2b (6.5 x10
5 














for 3 weeks. The dose of IFN-α-2b used was comparable to that used for therapeutic purpose 
[22].
 
Group VK2 received 10 mg/kg vitamin K2 
[23] 
by gavage, daily 3 times per day for 3 weeks 
(vitamin K2 was previously dissolved in corn oil). Group IFN+VK2 received both drugs at the 
doses administered individually. 
At the end of the ninth-week of treatment rats were bled through a cardiac puncture 
after administration of ketamine-xylazine (70 mg/kg body weight and 2.1 mg/kg body weight, 
respectively), and livers were removed and processed.  
 
Immunohistochemical studies 
Quantitation of AHF 
rGST-P has been described as the most effective single marker of hepatic preneoplasia in the 
rat. Thus, immunohistochemical detection of rGST-P is the most widely used method for 
identification, quantitation and assessment of rat altered hepatic foci (AHF) 
[24].
 Liver slices 
from different lobes were fixed in 10% v/v formalin solution and embedded in low melting 
paraffin. Immunohistochemical staining was performed using the antibody raised against rGST-
P. The slices were incubated with biotinylated goat anti-rabbit secondary antibody and then with 
horseradish-peroxidase-conjugated streptavidin (HRP CytoScan Detection Kit, Cell Marque). 
Signals were detected with DAB Sustrate Kit (Cell Marque) followed by hematoxylin 
counterstaining. A representative number of field sections (usually between 1 to 1.5 cm
2
 of 
tissue) was evaluated per animal. Images were collected using a CCD color video camera (Sony 
SSC-c370) attached to a Zeiss Axiolab microscope. Images were processed using a NIH 
imaging analysis system (ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA). The number of AHF per liver and AHF as percentage of liver were calculated according 
to the modified Saltykov's method 
[25]
 using the digitized images. 
 
Determination of proliferative index 
To investigate differences in proliferation activity in rGST-P-positive foci between the 














with anti-rGST-P and anti-PCNA antibodies. PCNA was visualized by the method of Greenwell 
et al. 
[22]
 using as primary antibody anti-PCNA from Santa Cruz Biotechnology (Santa Cruz, 
CA). A representative number of random fields of liver sections (400X magnification) were 
evaluated and scored. All PCNA-positive cells in G1, S, M, and G2 phases were combined as 
total proliferating cells. The number of proliferating cells within rGST-P-positive lesions was 
determined by examining at least 1,000 hepatocytes. Proliferative index (PI) was expressed as 
proliferating cells scored per 1,000 hepatocytes. 
For Bcl-2 immunohistochemistry, serially sectioned slides were examined by 
immunohistochemical staining with anti-rGST-P and anti-Bcl-2 antibodies. Bcl-2 was 
visualized by the method of Greenwell et al. 
[22]
 using as primary antibody anti-Bcl-2 from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
 
Hepatic collagen evaluation 
Liver fibrosis was evaluated by digital image analysis on sections stained with 1% Direct Red 
80/picric acid. This semi-quantitative technique allows the estimation of total amount of hepatic 
collagen using several microphotographs slices obtained from each liver slice, as previously 
described
[27]





Tissue samples were homogenized in 150 mM KCl with protease inhibitors. Cytosolic, 
mitochondrial, and nuclear extracts were prepared as described previously 
[28][29]
. The 
homogenates were centrifuged at 1,000g to remove unbroken cells, nuclei and heavy 
membranes. Nuclei were sedimented by centrifugation at 1,000g (First centrifugation). Pellets 
from first centrifugation were washed and resuspended in RIPA buffer containing 20 mmol 
phosphate-buffered solution (pH 8), 1% Triton, 1% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 5 mmol EDTA, 200 mmol NaCl, and protease inhibitors. Pellets were incubated on ice 
for 1 hour, and centrifuged (8,000g, 15 minutes, 4°C) to obtain nuclear fraction. Supernatant 














9,000g at 4°C for 15 minutes. Supernatant from this centrifugation was then washed in CaCl2 
0.1M and centrifuged at 27,000g and 4°C for 15 minutes. Pellet was discarded, and supernatant 
was kept as the cytosolic fraction.  
Protein concentration was determined by the Lowry method 
[30].
 Equal amounts of 
protein were subjected to electrophoresis on 12% SDS-polyacrylamide gels and transferred to 
polyvinylidene fluoride membranes (LD400 microplate reader, Beckman Coulter Inc, Fullerton, 
CA, USA). Membranes were blocked with T-PBS-10% nonfat milk, washed and incubated 
overnight at 4ºC with primary antibodies. Finally, membranes were incubated with peroxidase-
conjugated secondary antibodies and bands were detected by the ECL
TM
 detection system and 
quantified by densitometry using the Gel-Pro Analyzer software. Both, equal loading and 
protein transfer for each membrane were checked by incubations with the proper antibodies and 
by Ponceau S staining.  
 
Caspase-3 activity assay 
Caspase-3 activity was determined using EnzChek1 Caspase-3 Assay Kit #1 (Molecular Probes 
Inc., Eugene, OR, USA), according to the manufacturer’s suggestions. Briefly, hepatic total 
homogenates from each sample were mixed with substrate solution. Fluorescence was measured 
at an excitation wavelength of 360 nm and an emission wavelength of 465 nm in a DTX 880 
multimode detector (Beckman Coulter Inc, Fullerton, CA, USA). 
 
Statistical Analysis 
Data are presented as means ± SEM. Statistical significance was evaluated by unpaired two-
tailed Student’s test. Time course studies were evaluated by two-way ANOVA followed by 
Bonferoni post-test (GraphPad PRISM® 4 software), p value <0.05 was interpreted as a 
















During the experiment, food consumption was similar in all groups and no signs of dehydration 
were observed along the treatment (data not shown). The ratio liver/body weight was similar in 
all groups. H&E staining and further examination of the liver showed basically no differences 
between livers from all different groups (Fig. 1B) with no signs of acute or chronic 
inflammation in spite of the AHF development (arrows). We found non-significant differences 
in the activity of the hepatic enzymes AST and ALT in plasma (Fig 1C).  
 
Vitamin K2 blocks IFN-α-2b-induced reduction in size and volume of the AHF  
Changes in number and volume percentage of the liver rGST-P-positive foci are shown in Fig 2. 
The number and volume percentages of AHF per liver in IFN group were significantly 
decreased compared to IP group (-39% and -65%, respectively). Surprisingly, VK2 did not 
show any differences on the number and volume percentages of AHF per liver respect to IP 
group, alone (VK2 group) or combined with IFN (IFN+VK2 group). Furthermore, the animals 
that received both drugs showed a trend toward an increment in number and volume percentages 
of AHF per liver, although this trend was not statistically significant. 
 
Vitamin K2 does not improve total collagen deposition  
Collagen deposition upon the different treatments is shown in Fig. 3. As expected, IFN-α-2b 
treatment markedly reduced hepatic collagen deposition, therefore the degree of fibrosis 
compared to IP rats (-32 %). In line with results for the number and volume percentage of liver 
occupied by AHF, VK2 alone did not show any effects on collagen deposition. However, a 
reduction was observed for the combined IFN+VK2 group (-31%), similar to IFN group, 
indicating that the vitamin treatment did not have an additive action on the beneficial effects of 
IFN-α-2b.  
 














As previously shown, immunoblot analysis of proapoptotic protein Bax, showed an increase in 
mitochondrial protein expression in IFN as well as in IFN+VK2 groups (+219% and +97% 
respectively) respect to IP. No changes were observed in VK2 group (Fig. 4A). Levels of 
cytosolic cytochrome c were evaluated by immunoblotting. Cytosolic cytochrome c increased in 
IFN group compared to IP animals (+135%); the other groups did not show any differences 
respect to IP (Fig 4B). 
It was previously demonstrated that p53 induces apoptosis in HCC 
[31]
. To determine 
whether p53 is a major mediator of apoptosis in preneoplastic foci of rats treated with IFN-α-2b, 
we performed immunoblot analysis of p53 using nuclear fractions. Administration of IFN-α-2b 
increased the expression of p53 (+75, 2%) protein compared to IP group, whereas vitamin K2 
treatment reduced the levels (-54, 3%) of the protein (Fig 4C).  
Also, the caspase cascade is now believed to be the main phatway by which the 
apoptosis is orchestrated. The most prevalent caspase in the cell is caspase 3 
[32].
 We determined 
caspase 3 activity in all studied groups. Fig. 4D shows that caspase-3 activity was significantly 
increased in IFN group respect to IP animals. Vitamin K2 had no effects on caspase-3 activity in 
any of the other groups.  
 
Vitamin K2 blocks the apoptotic effect of IFN-α-2b through an induction of the 
antiapoptotic protein Bcl-2 
Regarding the antiapoptotic protein Bcl-xL, no significant differences were observed for any 
groups; however, a non-statistically significant trend to a decrease was observed in the IFN 
group respect to the IP group (Fig 5A). The analysis of the antiapoptotic protein Bcl-2 showed 
an increase in mitochondrial protein expression in VK2 (+94%) and IFN+VK2 (+43%) groups 
(Fig. 5B). Interestingly, when Bcl-2 was evaluated by immunohistochemistry, we found a very 
interesting distribution pattern. An astonishing staining outside the AHF was observed the IP 
group. IFN group, however, presented with less stained cells, but Bcl-2-possitive cells were 














group; but in contrast, many Bcl-2-positive cells were found within the AHF. A similar pattern 
in the combined group was observed (Fig. 5C). 
Finally, Bax/Bcl-2 ratios were calculated for each group. Setting arbitrarily IP ratio as 1, 
we found a significant increase only in IFN group ratio (3.2±0.2), reinforcing our previous 
results where IFN-α-2b induced apoptosis in preneoplastic livers in rats (Fig 5D). 
 
Vitamin K2 does not affect cell proliferation and the cell cycle 
Fig. 6A and table 1 show the analysis of PCNA protein by both immunoblotting and 
immunohistochemistry, respectively. Immunoblotting showed no differences in the expression 
of PCNA protein between all the studied groups. In line, no changes were observed in the PI 
within the foci. 
One proposed antitumoral mechanism of vitamin K2 is its ability to arrest the cellular 
cycle 
[6]
, thus, we measured the expression of two key proteins involved in the cycle: cyclin D1 
and p27. Analysis of protein expression in nuclear extracts showed no differences in the 
expression of cyclin D1 protein in any of the studied groups (Fig. 6B). There was an increase in 
p27 protein in IFN group respect to IP group (+113%) (Fig. 6C). However, its expression level 
















Today, chemotherapy remains one of the main approaches for the treatment of HCC 
[33]
. Despite 
the significant advances in HCC management lately, there are no effective chemoprevention 
policies, and only sorafenib treatment has been approved for patients with advanced tumors 
[34]
. 
However, sorafenib efficacy is now on debate since despite the survival benefit (3 months, vs. 
placebo patients)
 [35]
, resistance and intolerance to sorafenib are very common. Thus, new and 
old systemic therapies need to be (re)considered for HCC patients with resistance or intolerance 
to sorafenib.  
The use of antivirals and vaccination has successfully diminished the incidence of 
hepatitis B-related HCC 
[34]
. In this sense, IFN-α has been clinically used for delaying the 
progression of liver function impairment or for the prevention of HCC development in patients 
with chronic hepatitis B or C 
[36][37]
. The clinical outcome of IFN-α monotherapy has not been 
satisfactory 
[38]
; however, several studies have reported a strong antitumor activity and survival 
benefit of IFN-α-based combination therapy in HCC 
[39][40]
. Also, patients undergoing IFN-α-2b 
treatment are susceptible to several secondary effects
 [37]
. Thus, combining certain alternative 
medicinal therapies, such as vitamins, with conventional therapies is a common choice for many 
cancer patients. It is believed that these complementary therapies strengthen the general 
weakness from such patients. 
In line, several clinical trials have attempted to elucidate the role of vitamin K2 in 
preventing the development of HCC in women with viral cirrhosis, and also the suppression of 
recurrence of HCC, leading to a greater survival  
[41][42]
; however, results are still controversial 
[42]–[44]
. 
Our group has been devoted to the study of the early stages of liver carcinogenesis for 
many years. In this sense, we found that administration of IFN-α-2b during the development of 
hepatic preneoplasia prevents the increment in the number and size of AHF 
[21][45]
. In this study, 
we sought to evaluate the effect of IFN-α-2b administered after the end of the carcinogenic 
treatment, in order to compare the reversion effect of IFN-α-2b rather than the prevention effect. 














model of early hepatocarcinogenesis. In addition, we also evaluated the revertive effect of 
vitamin K2 using the same model, and studied whether the combination of both compounds had 
a beneficial (additive or synergic) effect on liver cancer development compared to the individual 
treatments. In these sense, we found interesting but unexpected results, since combination of 
IFN-α-2b and vitamin K2, at previously individually tested doses 
[21][23]
, did not show any 
beneficial effects on the development of liver cancer. Furthermore, vitamin K2 seems to have a 
blocking effect on here presented and also all the previously reported IFN-α-2b actions 
[21][28][45]
. 
Here, we reported that vitamin K2 blocks IFN-α-2b-induced reduction in size and 
volume of the AHF. A very thorough study of the vitamin K2 dose to be administered was made 
before the start of the treatments. Doses ranging between 3 mg/Kg to 20 mg/Kg were found in 
literature. Based on the AHF reducing effect of vitamin K2, we used the dose of 10 mg/Kg body 
weight administered 3 days a week for 3 weeks. Yoshiji et al. reported an AHF reducing effect 
using 3 mg/Kg after a partial hepatectomy during 8 weeks
 [16]
. Despite we used 10 mg/Kg; 
vitamin K2 was not able to reduce the number or the volume of the AHF. However, it is 
interesting to note that vitamin K2 combined with IFN-α-2b had absolutely any effect on the 
development of the AHF; this is, AHF sizes and numbers were not different from the foci from 
IP livers, showing that vitamin K2 would signal though a pathway interfering with the IFN-α-2b 
signaling pathway. 
IFN-α is an interesting agent against liver fibrosis. Intrinsic antifibrogenic properties of 
this compound has been established by in vitro studies 
[46][47]
. Indeed, IFN-α exerts its 
antifibrogenic effects in different rat models of hepatic fibrosis 
[48][49]
 and also in patients with 
hepatitis C virus 
[50]
.We previously found that IP rats presented exacerbated liver fibrosis 
compared to control rats 
[51]
. In this study, we showed that IFN-α-2b treatment improved the 
deposition of total collagen in IP rats. Interestingly, vitamin K2 had no effect on collagen 
deposition, neither alone or with IFN-α-2b. In this regard, to our knowledge, it was never 
reported a beneficial effect of vitamin K2 on collagen deposition. Even more, it was claimed 
















Vitamin K2 induces apoptosis in a wide range of tumoral cells 
[7][54]–[58]
. Unexpectedly, 
we did not find any signs of apoptosis induced by vitamin K2 in our model. As previously 
shown in a model of prevention of hepatocarcinogenesis 
[21]
 , here we found that IFN-α-2b 
induces Bax translocation to the mitochondria in livers from IP rats, inducing apoptosis; 
however, in this model the combination with vitamin K2 seemed to block IFN-α-2b apoptotic 
effect. When other apoptotic proteins and activities were studied, we found a similar pattern, 
were IFN-α-2b induced-apoptosis is blocked by vitamin K2, with no apoptotic effect of the 
vitamin alone. In this sense, it was previously reported that vitamin K2 did not show apoptosis 
on Huh7 cells, where the effect appears only when vitamin K2 is combined with another 
compound 
[59]
. When p53 protein expression was evaluated, vitamin K2 alone induced a marked 
decrease in protein expression.  
Finally, we found that the levels of anti-apoptotic protein Bcl-2 were increased when IP 
rats were treated with vitamin K2 alone. This increment impairs the mithocondrial apoptotic 
pore formation leading to a decreased or null apoptosis activation 
[60]
. Furthermore, when the 
hepatic apoptotic index was calculated, no global effects of vitamin K2 on apoptosis were 
found, showing once again that vitamin K2 has a blocking effect on the IFN-α-2b-induced 
apoptotic effect.  
It is interesting to note that Bcl-2 acts inhibiting vitamin K2 apoptotic action. 
Furthermore, it was demonstrated that the antitumor effect of vitamin K2 might be improved by 
silencing BCL-2 expression in HCC 
[61]
.  
Besides, programmed cell death is facilitated in part through the production of free 
radicals via oxidative pathways. In this connection, it has been proposed that Bcl-2 acts 
inhibiting cell death by interfering with the production of oxygen-derived free radicals induced 
by a wide variety of stimuli such as IFN-α-2b 
[45][62]
.  
Although it was shown that vitamin K2 induced growth inhibition via cell cycle arrest 
and apoptosis in a dose dependent manner for glioma cells in both rat and human cell types 
[63]
, 
in this study we found no changes in cell proliferation in livers from IP rats treated or not with 














proliferation inside liver tumors. Authors claimed that in order to pursue its antiproliferative 
effects, doses of vitamin K2 should be extremely elevated compared to those used clinically 
[16]
. 




It is interesting to note that naturally occurring vitamins K had poor effect on cell 
growth and none on the cyclins 
[64]
. Furthermore, vitamin K2 administered together with IFN-α 
in cell lines presented with little effect on cell cycle 
[65]
. In this study; however, we showed that 
vitamin K2 administration in the early stages of liver cancer development, has no effect on cell 
proliferation or apoptosis. Even more, combination with IFN-α-2b seemed to block the 
antiapoptotic effects of IFN-α-2b, through a mechanism linked to an increase in the 
antiapoptotic protein Bcl-2. Since both agents are widely used in clinical practice, this 
combination regimen may be evaluated against HCC in the future. 
In summary, we did not see a beneficial effect as a result of treating IP rats with vitamin 
K2, alone or in combination with IFN-α-2b, since there is no decrease in the number and size of 
foci, decrease in proliferation, or increased apoptosis. Furthermore, it seems clear that vitamin 
K2 interferes in IFN-α-2b cellular actions. In this sense, we believe there is an unknown 
interaction between the signaling pathways of IFN-α-2b and vitamin K2 that leads to the 
modulation of other signaling pathways with undesired final effects. This interaction might be 
mediated by the antiapoptotic protein Bcl-2. 
Our findings are interesting in many ways. First, this is the only study performed in rats 
evaluating the effects of IFN-α-2b and vitamin K2 combined therapy on the early stages of liver 
carcinogenesis. Second, this study highlights that supportive vitamin supplements/therapies are 
not always safe, as they could put at risk the life of patients treated with IFN-α-2b. Finally, 
administered doses should be studied careful and individually in order to decrease at a 
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Figure 1. No signs of liver damage in animals undergoing hepatic preneoplasia. A) Animal 
treatment protocol. Male Wistar rats were subjected to a two-stage model of 
hepatocarcinogenesis. IP group received two intraperitoneal doses of DEN (150 mg/Kg body 
weight) 2 weeks apart. One week after the last injection, the animals received 20 mg/Kg body 
weight of 2-AAF by gavage during 3 consecutive days per week for 3 weeks.  Group IFN: IP 
rats received IFN-α-2b 6.5x10
5
 U/kg intraperitoneally 3 times per week for 3 weeks (weeks 6 to 
9); Group VK2: IP rats received 10 mg/kg vitamin K2 orally 3 times per day for 3 weeks 
(weeks 6 to 9); and Group IFN+VK2: IP rats received both compounds at equal doses as per 
separate. The animals were sacrificed at the end of week 9. B) Liver H&E staining for 
evaluation of hepatic architecture (100X). No signs of acute or chronic inflammation despite the 
AHF development (arrows). C) Plasma transaminase levels, as a hepatic damage marker.  
 
Figure 2. Liver immunohistochemical study of rGST-p expression. A) Representative 
images showing the size of rGST-p-positive foci in IP, IFN, VK2, and IFN+VK2 groups, 
magnification 100X. Changes in (B) number of AHF per liver and (C) percentage of liver as 
AHF. Each bar indicates mean ± SEM. *p<0.05 vs IP group. 
 
Figure 3. Study of collagen deposition in the liver. A) Representative images of liver collagen 
deposition. Collagen fibers are showed in red color (arrows), magnification 200X. B) Total liver 
collagen estimation. Each bar represents the mean ± SEM. *p<0.05 vs IP group. 
 
 Figure 4. Analysis of hepatic proapototic markers. A) Study of Bax mitochondrial levels, 
(B) cytochrome c cytosolic levels and (C) p53 nuclear levels by immunoblotting. The bars 
below each immunoblot panel represent the densitometric analysis of the bands. Each bar 
represents the mean ± SEM. *p<0.05 vs IP group. D) Caspase-3-like activity in hepatic total 
homogenates. Data are expressed in percent values as mean ± SEM; caspase-3 activity in IP 















Figure 5. Analysis of hepatic antiapoptotic markers. A) Expression levels of Bcl-XL, and (B) 
Bcl-2 in liver mitochondrial fractions by immunoblotting. The bars below each immunoblot 
panel represent the densitometric analysis of the bands. (C) Immunostaining for Bcl-2. 
Immunohistochemistry was performed using paraffin-embedded liver sections. The arrows 
show the presence of the AHF (100X). D) Bar graph showing the ratio between optical density 
for Bax bands over Bcl-2 bands for individual immunoblottings (apoptotic index): Bax/Bcl-2. 
Results are expressed relative to IP group, to be considered 1. Bars represent mean ± SEM. 
*p<0.05 vs IP group. 
 
Figure 6. Analysis of cellular proliferation and cell cycle proteins. A) Immunoblotting for 
PCNA, (B) cyclin D1, and (C) p27 proteins in liver nuclear fractions. Bars represent mean ± 
SEM. *p<0.05 vs IP group. 
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